Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of CVX1 vaccine with or without immune checkpoint inhibitor in muscle-invasive bladder cancer or localized/locally advanced renal cell cancer
NL-OMON59940Phase 1Recruiting
- Sponsor
- CimCure
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of NL-CVX1, sponsored by CimCure. Started Apr 2026; status: recruiting.
02
Drugs
NL-CVX1
Beyond the preview
Go deeper on NL-OMON59940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59940.